Miguel A. Villalona MD FACP, FAAAS

Oncology•Orange, CA

Thoracic Cancer

Division Chief Hematology/Oncology

Join to View Full Profile

200 S Manchester Avesuite 400, ZOT4061Orange, CA 92868
Phone+1 714-456-5153

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1995
University at BuffaloFellowship, Hematology and Medical Oncology, 1990 - 1992
University of MinnesotaFellowship, Hematology and Medical Oncology, 1989 - 1990
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1986 - 1989
Universidad Nacional Pedro Henriquez UrenaClass of 1985

Certifications & Licensure

CA State Medical License 2020 - 2026
FL State Medical License 1998 - 2025
KY State Medical License 2020 - 2021
OH State Medical License 1999 - 2017
TX State Medical License 1995 - 2010
AL State Medical License 1992 - 1996
MN State Medical License 1989 - 1994
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow American Association for the Advancement of Science
Fellow American College of Physicians
Premio Fray Anton de Montesinos Asociacion de egresados UASD NYC
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Join now to see all

Clinical Trials

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 2
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors Start of enrollment: 2000 Nov 01
Completed
Phase 1
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma Start of enrollment: 2001 Jul 01
Completed
Phase 1, Phase 2
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 2
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Start of enrollment: 2009 Mar 01
Completed
Phase 2
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors Start of enrollment: 2017 Nov 03
Completed
Phase 2
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab Start of enrollment: 2022 Sep 01
Recruiting
Phase 1
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Start of enrollment: 2022 Jul 20
Active, not recruiting
Phase 1
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2000 Sep 01
Completed
Phase 2
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 1
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Start of enrollment: 2022 Apr 14
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Safety and efficacy of a selective inhibitor of cyclin-dependent kinase 9 (KB-0742) in patients with recurrent or metastatic adenoid cystic carcinoma.
Glenn J Hanna, Gregory M Cote, Rashmi Chugh, Jacob S Thomas, Jyoti Malhotra
Cancer Research Communications. 2025-04-25
1 citations
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors.
Miguel A Villalona-Calero, Lei Tian, Xiaochen Li, Joycelynne M Palmer, Claudia Aceves
JCI Insight. 2025-02-04
2 citations
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2025-02-01

Press Mentions

Topical Gel Soothes Skin Rash for CRC Patients on EGFR InhibitorsApril 30th, 2025
New Advances in Treating Lung Cancer, the Deadliest CancerMay 20th, 2016

Grant Support

Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint InhibitorsUNIVERSITY OF CALIFORNIA-IRVINE2022–2027
Phase 1 evaluation of Enhanced Natural Killer Cells as a treatment strategy in non-small cell lung cancer patients refractory to PD-1/PD-L1 Immune Checkpoint InhibitorsNCI2022–2027
Phase 1 and 2 molecular and clinical pharmacodynamic trials ET-CTNNIH/NCI2020–2024
Targeting Somatic Homologous Recombination In Solid TumorsNational Cancer Institute2010–2012
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2011
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2010
Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8472Division Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment2009
Biomodulation Of Capecitabine By Docetaxel In Non-Small*National Cancer Institute2004–2005
TNF Blockade In Pancreatic Cancer PatientsNational Cancer Institute2003–2004
Phase II Randomized Trial Of CPT-11 And Mitomycin CNational Cancer Institute2002–2003
Phase I Study Of Sequential CPT 11 &Mitomycin CNational Center For Research Resources1999–2002
Translational Research In Lung CancerNational Cancer Institute1998–2002
Phase I Study To Determine The Safety Of Ecteinascidin-743National Center For Research Resources1997–2000
Phase I Protocol To Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources1998–1999
Phase I Trial Of PN401 As Rescue Agent For Escalating Doses Of 5-FUNational Center For Research Resources1997–1999
Translational Research In Lung CancerNational Cancer Institute1997–1998
Phase I Protocolto Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources1997
Effect Of H Corticotropin Releasing Factor On Peritumoral BrainNational Center For Research Resources1996